Zhitong Finance App News, Jingfang Pharmaceutical-B (02595.HK) issued an announcement. The board of directors of the company noticed a recent increase in the price of the company's shares and would like to inform the company's shareholders and potential investors about the latest business developments of the Group. The company's clinical project, GFH375 combined with cetuximab, was included in the Breakthrough Therapy (BTD) list by the Drug Evaluation Center of the State Drug Administration on September 18, 2026 to treat KRAS G12D mutant metastatic colorectal cancer that has previously failed chemotherapy based on oxaliplatin, fluorouracil, and irinotecan. The clinical project was applied for on August 13, 2026, and the publication deadline is September 24, 2026.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.